v3.26.1
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Balances, at Beginning of period at Dec. 31, 2024 $ 408,964 $ 7 $ 843,920 $ 143 $ (435,106)
Balances, at Beginning of period (in shares) at Dec. 31, 2024   74,312,608      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exchange of common stock shares for pre-funded warrants (in shares)   (6,070,000)      
Stock-based compensation expense, including employee stock purchase plan expense 9,070   9,070    
Issuance of shares under employee stock purchase plan 748   748    
Issuance of shares under employee stock purchase plan (in shares)   206,609      
Exercise of stock options 470   470    
Exercise of stock options (in shares)   178,669      
Issuance cost associated with private equity placement (14)   (14)    
Net unrealized gain (loss) on marketable securities 171     171  
Net loss (74,173)       (74,173)
Balances, at End of period at Jun. 30, 2025 345,236 $ 7 854,194 314 (509,279)
Balances, at End of period (in shares) at Jun. 30, 2025   68,627,886      
Balances, at Beginning of period at Mar. 31, 2025 383,452 $ 7 848,520 420 (465,495)
Balances, at Beginning of period (in shares) at Mar. 31, 2025   68,333,065      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense, including employee stock purchase plan expense 4,692   4,692    
Issuance of shares under employee stock purchase plan 748   748    
Issuance of shares under employee stock purchase plan (in shares)   206,609      
Exercise of stock options 234   234    
Exercise of stock options (in shares)   88,212      
Net unrealized gain (loss) on marketable securities (106)     (106)  
Net loss (43,784)       (43,784)
Balances, at End of period at Jun. 30, 2025 345,236 $ 7 854,194 314 (509,279)
Balances, at End of period (in shares) at Jun. 30, 2025   68,627,886      
Balances, at Beginning of period at Dec. 31, 2025 478,559 $ 8 1,075,487 621 (597,557)
Balances, at Beginning of period (in shares) at Dec. 31, 2025   81,376,449      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exchange of pre-funded warrants for common stock shares (in shares)   3,500,000      
Stock-based compensation expense, including employee stock purchase plan expense 23,051   23,051    
Issuance of shares under employee stock purchase plan 652   652    
Issuance of shares under employee stock purchase plan (in shares)   62,778      
Issuance of shares under at-the-market offering, net of issuance costs of $25 41,918   41,918    
Issuance of shares under at-the-market offering, net of issuance costs of $25 (in shares)   1,712,739      
Exercise of stock options $ 4,241   4,241    
Exercise of stock options (in shares) 804,607 800,200      
Net unrealized gain (loss) on marketable securities $ (1,568)     (1,568)  
Net loss (116,289)       (116,289)
Balances, at End of period at Jun. 30, 2026 430,564 $ 8 1,145,349 (947) (713,846)
Balances, at End of period (in shares) at Jun. 30, 2026   87,452,166      
Balances, at Beginning of period at Mar. 31, 2026 480,478 $ 8 1,131,576 (460) (650,646)
Balances, at Beginning of period (in shares) at Mar. 31, 2026   87,332,971      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense, including employee stock purchase plan expense 12,903   12,903    
Issuance of shares under employee stock purchase plan 652   652    
Issuance of shares under employee stock purchase plan (in shares)   62,778      
Exercise of stock options 218   218    
Exercise of stock options (in shares)   56,417      
Net unrealized gain (loss) on marketable securities (487)     (487)  
Net loss (63,200)       (63,200)
Balances, at End of period at Jun. 30, 2026 $ 430,564 $ 8 $ 1,145,349 $ (947) $ (713,846)
Balances, at End of period (in shares) at Jun. 30, 2026   87,452,166